We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2012 by Rasha Mohammed Mohammed Badawi, Ain Shams University.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01612390
First Posted: June 5, 2012
Last Update Posted: June 5, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Ain Shams University
Information provided by (Responsible Party):
Rasha Mohammed Mohammed Badawi, Ain Shams University
June 2, 2012
June 5, 2012
June 5, 2012
August 2012
August 2013   (Final data collection date for primary outcome measure)
reduce blood loss during third and fourth stages of labor. [ Time Frame: 1 year ]
reduce blood loss during third and fourth stages of labor by using misopristol is better than using oxytocin
Same as current
No Changes Posted
the duration of the third stage of labor ,need for oxytocics ,blood transfusion and any adverse effects of the drugs [ Time Frame: 1 year ]
the duration of the third stage of labor ,needed for oxytocics ,blood transfusion and any adverse effects of the drug will be reduced with mesopristol
Same as current
Not Provided
Not Provided
 
Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor
Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor
Sublingual misoprostol is superior to oxytocin in reduction of blood loss during the third and fourth stages of labor
Sublingual misoprostol is superior to oxytocin in reduction of blood loss during the third and fourth stages of labor as The data from a pharmacokinetics study suggested that the bioavaiblitiy of misoprostol after sub-lingual administration was higher than those after oral or vaginal administration
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
The study will include (180)randomly allocated
Postpartum Hemorrhage Prevention by Using Oxytocin Verses Misoprostol
Not Provided
  • group 1
    receive 400 Mg sublingual misoprostol.
  • group 2
    receive 600 Mg sublingual misoprostol.
  • group 3
    receive 5IU of intravenous oxytocin.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
180
December 2013
August 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women with aheathy singleton pregnancy in spontaneous or induced labor at term .

Exclusion Criteria:

  • Hypersensitivity/Contraindication to prostaglandins Antepartum hemorrhage Multiple pregnancy Cardiac disease Malpresentation Rhesus- negative mother hypersensitive disorders Severe anaemia(hemoglobin<7g/dl)
Sexes Eligible for Study: Female
18 Years to 40 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Egypt
 
 
NCT01612390
hit 1234
Yes
Not Provided
Not Provided
Rasha Mohammed Mohammed Badawi, Ain Shams University
Rasha Mohammed Mohammed Badawi
Ain Shams University
Principal Investigator: RBadawi mohamed, M.B;B.CH Ain Shams University
Ain Shams University
June 2012